A recently published study shows promise for those monitoring studies involving Alzheimer’s disease, the insidious condition that robs us of the most precious human asset, the memory. What follows is a brief TrialSite breakdown of the study results based on a recent entry in the university’s news by Julia Milze.
The study reflects the use of a cancer drug called Sargramostim (GM-CSF) has shown “Sargramostim treatment leads to innate immune system activation, cognition and memory improvement, and partial normalization of blood measures of amyloid and tau pathology and neuronal damage in participants with mild-to-moderate Alzheimer’s disease.”
The study was relatively small, but wider testing is planned in a hope that this approach may offer some mitigation to Alzheimer’s loss of cognition and memory.